CFO Kyle Piskel sells 162,820 shares of ADPT at $19.50 (3.2M), retaining 216,637 shares post-sale
Kyle Piskel, CFO of Adaptive Biotechnologies, sold 162,820 shares at $19.50 on 2025-11-28 for a total value of $3,174,990.00, reducing his holdings by 42.9% from 379,457 to 216,637 shares. The sale occurred near the upper end of the company's 52-week range ($5.73–$20.46), at a price only 8.6% below the 52-week high. The stock has appreciated 45.4% over the past 90 days and 7.7% over the past 30 days, suggesting the transaction took place amid recent upward momentum. Despite the sale's magnitude, the CFO retained substantial holdings (216,637 shares), maintaining material skin-in-the-game; context on whether this transaction was discretionary or scheduled under a 10b5-1 plan would be relevant to understanding the timing signal.